Open Access

Effect of bacterium in the malignant wounds of soft tissue sarcoma

  • Authors:
    • Eiji Nakata
    • Tomohiro Fujiwara
    • Haruyoshi Katayama
    • Takuto Itano
    • Toshiyuki Kunisada
    • Toshifumi Ozaki
  • View Affiliations

  • Published online on: August 17, 2022     https://doi.org/10.3892/ol.2022.13465
  • Article Number: 345
  • Copyright: © Nakata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant wounds (MWs) are rare skin lesions, which accompany ulceration, necrosis and infection caused by infiltration or damage by malignant tumor. The present study aimed to investigate the bacterial etiology implicated in MW in soft tissue sarcoma (STS), and the effectiveness of culture‑guided perioperative antibacterial administration. A retrospective evaluation was conducted on medical records of patients who presented with MW between 2006 and 2020. A total of seven patients were included in the present study, in whom all tumors were relatively large (>5 cm) and high‑grade. Subsequently, five patients underwent limb‑sparing surgery, and three patients had distant metastases with a 5‑year overall survival of 71%. Preoperative microbiological sampling from the wound identified 11 different bacterial strains in five patients. The infections were polymicrobial with an average of 2.6 strains isolated per patient (1 aerobic, 1.6 anaerobic bacteria). They were predominantly methicillin‑sensitive Staphylococcus aureus. Patients with MWs from STS reported symptoms, including bleeding (71%), exudation (71%) and malodorous wound (43%) at the initial presentation; these completely resolved after surgery. All but one patient reported pain at the MW site with an average numeric rating scale of 4.4 at presentation that decreased to 1.4 (P=0.14) and 0.6 (P=0.04) one and two weeks after surgery, respectively. The patients had elevated C‑reactive protein (71%), anemia (57%), low albumin (86%) and renal/liver dysfunction (14‑29%). One patient was diagnosed with sepsis. Surgical resection afforded symptomatic relief and resolution of abnormal laboratory values. Although selected antibiotics were administered in four patients based on the preoperative antibiotic sensitivity test, surgical site infection (SSI) occurred in three patients. Therefore, the effectiveness of the selected antibiotics based on the results of the preoperative culture in preventing SSI needs to be investigated in the future. In conclusion, physicians should keep in mind that although surgical resection can improve the symptoms and abnormal values in laboratory examination form MW, it is accompanied with a high rate of SSI and poor prognosis.

Introduction

Malignant wounds (MWs) are lesions caused by malignant tumors infiltrating or damaging the skin (13). MWs are often accompanied by ulcerations, necrosis, hemorrhage, and inflammation (1,2). It is estimated that 5–7% of cancer patients experience MWs, especially patients with breast cancer, soft tissue sarcoma (STS), head and neck cancer, and melanoma (1,2). Previous studies mainly enrolled patients with limited life expectancy due to unresectable advanced or metastatic breast and skin cancers (4,5). Some studies reported an incidence of 3–4% for MW in patients with STS (69).

MWs are often infected because necrotic tissue provides a suitable environment for bacterial growth. Patients frequently report symptoms as malodorous wounds, exudation, pain, and bleeding. These symptoms lead to impaired mobility, emotional distress, and a poor quality of life (35). Fromantin et al proposed that MWs in patients with breast cancer had polymicrobial colonization predominated by Staphylococcus aureus and Pseudomonas aeruginosa (4). Biofilms were present in the wounds of 35% of the patients, and the concentration of bacteria correlated with the emergence of odor and pain. Few studies have focused on the bacteriological investigation of MWs in patients with STS (1012). Lutchminarian et al reported that the most common pathogen in MW from STS was Staphylococcus aureus (33%), followed by β-hemolytic Streptococcus (17%), and Pseudomonas aeruginosa (17%) (13). These infections sometimes lead to severe clinical problems, such as sepsis and surgical site infection (SSI) (10,12). Elfallal et al reported a case of life-threatening sepsis from severe necrotic wound in a patient with giant angiolipoma of the back (14). Immediate tumor excision with hemostasis was required. This supports the need for early diagnosis and treatment of concurrent sepsis. The effectiveness of sensitivity-guided perioperative antibacterial prophylaxis remains unclear. Data on perioperative improvement of clinical symptoms and laboratory data are lacking.

MWs have some oncologic features in STS; thus, it is important to manage both oncologic and infectious problems. In previous reports, patients with MWs from STS were older (mean age: 65–73 years), and presented with higher grade, higher stage, and higher proportion of metastases (20–33%) compared to those without MWs (1518). When the lesions are large, possibly requiring skin reconstruction, limb salvage was sometimes difficult, leading to a high rate of amputation (13–33%) (1518). Although resection of the tumor can control the symptoms associated with MWs, previous studies reported high rates of surgical site infection (SSI) as much as 26–42% (15,18). Hoshi et al reported 42% incidence of postoperative (SSI), and Candida species was the most common isolate, followed by Pseudomonas aeruginosa and Enterococcus species (18).

Therefore, this study aimed to perform microbiological analyses in a series of STS patients with MWs. We specifically investigated the bacterial profile in MWs and the effectiveness of sensitivity-guided perioperative antibacterial prophylaxis. Lastly, we investigated the incidence of sepsis and the changes in laboratory values after treatment.

Materials and methods

Study design and setting

We retrospectively evaluated the medical records of patients who presented with MWs at Okayama University Hospital (Okayama, Japan) between April 2006 and April 2020.

Study population

Patients who had pathologically confirmed MW and underwent surgical resection for STS in the extremity were included in the study. The exclusion criteria were as follows: (a) only conservative management done; (b) follow-up less than two years post-surgery; (c) development of MW during the clinical course. Finally, seven patients (four males, three females) were included in this study (Table I). Their median age at the start of treatment was 59 years (range, 30–78). Histological diagnosis was established according to the WHO Classification (19). Myxoid liposarcoma was diagnosed in two patients, and myxofibrosarcoma, undifferentiated pleomorphic sarcoma (UPS), fibrosarcoma, angiosarcoma, leiomyosarcoma, and malignant peripheral nerve sheath tumor (MPNST) was diagnosed in one patient each. The median tumor size was 10 cm (range: 6–31) and was superficial in 5 patients and deep in 2 patients. The grade was determined using the French Fédération Nationale des Centres de Lutte Contre Le Cancer (FNCLCC) grading system; grade 2 cancer was observed in three patients and grade 3 in four patients (20). The American Joint Committee on Cancer (AJCC) stages were IIIA in four patients and IV in three patients. The locations of the tumor were as follows: the thigh (4), each upper arm (1), lower leg (1), and abdomen (1). No patient had a treatment history of hypertension, diabetes mellitus (DM), renal disorder, liver disorder, or respiratory disorder. The median follow-up period was 53 months (range: 4–152 months).

Table I.

Patient characteristics.

Table I.

Patient characteristics.

CaseSexAge, yearsHistologySize, cmLocationFNCLCCAJCCMarginReconstructionMetastasesOutcome
1Female75Myxoid liposarcoma17Thigh2IVR0Skin graftLymph nodeNED
2Female42Myxoid liposarcoma31Thigh2IVR0 (hip disarticulation) LungDOD
3Male76Undifferentiated sarcoma8Thigh3IIIAInitial surgery; R0 Recurrence; R0 (hip disarticulation)Latissimus dorsi flap + skin graftLung Soft tissue (follow up period)DOD
4Female59Fibrosarcoma9Thigh3IIIAR0Gastrocnemius muscle flap + skin graft DOA
5Male55Angiosarcoma10Lower leg3IVR0 (Amputation) Lymph node Bone Lung (follow-up period)DOD
6Male78 Myxofibrosarcoma10Upper arm2IIIAR0Latissimus dorsi flapLymph node (follow-up period)NED
7Male30Malignant peripheral nerve sheath tumor6Abdomen3IIIAR0 CDF

[i] FNCLCC, French Fédération Nationale des Centres de Lutte Contre Le Cancer; AJCC, American Joint Committee on Cancer; NED, no evidence of disease; DOD, dead of disease; DOA, dead of another disease; CDF, continuous disease free.

Microbiological sampling and testing

Preoperative microbiological samples were obtained from the necrotic zone of the wound. Detection of aerobic, facultative anaerobic, and strict anaerobic bacteria was carried out using a quantitative method. We investigated the incidence of SSI based on the definition provided by the Centers for Disease Control (CDC) (Table SI) (21).

Clinical investigation

We investigated the symptoms of the wound (e.g., bleeding, odor/exudate, and pain) and clinical condition (fever) on presentation and after surgery. Fever was defined as a temperature higher than or equal to 37.5°C. Pain was quantified using a 10-point numeric rating scale (NRS). The symptoms were documented at baseline, one, and two weeks postoperatively. Bleeding was reported in five patients, foul odor in three patients, and exudate in five (Table II). These symptoms disappeared after surgery. All but one patient had pain at the MW site during the initial presentation, with an average NRS of 4.4 (range: 0–10). It decreased after surgery; the average NRS were 1.4 (range: 0–10, P=0.14) and 0.6 (range: 0–3, P=0.04) after one and two weeks of surgery, respectively. During the last follow-up, all but one patient had pain at the surgical site. Two patients presented with fever, which defervesced one week after surgery.

Table II.

Characteristics of the malignant wound.

Table II.

Characteristics of the malignant wound.

CaseBleedingOdorExudateAwareness of the tumorDuration of the malignant wound
1-++24 months12 months
2+++36 months3 days
3+-+4 months3 days
4+-+36 months4 months
5+--7 months4 months
6-++13 months11 days
7+--4 months1 day

We investigated the presence of sepsis at the initial presentation. The diagnosis for sepsis was defined based on the Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020) (22). By this definition, suspected infection can be rapidly identified in the presence of two or more quick Sequential Organ Failure Assessment (qSOFA) score: A respiratory rate (≥22/min), altered mentation (Glasgow Coma Score ≤14), and a systolic blood pressure (≤100 mmHg) (2325). Next, the diagnosis of sepsis was confirmed when the SOFA score was ≥2 points higher in the presence of a clear infection or suspected infection (Table III). Septic shock was defined as persistent hypotension requiring vasopressors to maintain a mean arterial pressure of ≥65 mmHg and a serum lactate level >2 mmol/l (18 mg/dl) despite adequate volume resuscitation (22). One patient met the diagnostic criteria for sepsis (case 2).

Table III.

Sequential Organ Failure Assessment score.

Table III.

Sequential Organ Failure Assessment score.

Assessment score

Variables01234
Respiration
  PaO2/FIO2 (mm Hg)≥400<400<300<200<100
Coagulation
  Platelets (×103/l)≥150<150<100<50<20
Liver
  Bilirubin (mg/dl)<1.21.2-1.92.0-5.96.0-11.9≥12.0
Cardiovascular
  Mean arterial pressure (mmHg)≥70<70Dopamine ≤5 or dobutamine (any)Dopamine >5 or norepinephrine ≤0.1Dopamine >15 or norepinephrine >0.1
Nervous system
  Glasgow Coma Score1513-1410-126-9<6
Renal
  Creatinine (mg/dl)<1.21.2-1.92.0-3.43.5-4.9>5.0
  Urine output (ml/d) <500<200
Laboratory investigation

The following laboratory parameters were documented at baseline and 2–6 weeks after surgery: white blood cell (WBC) count, serum C-reactive protein (CRP), hemoglobin (Hgb), blood urea nitrogen (BUN), creatinine (Cr), albumin (Alb), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (T-bil). Anemia was defined as hemoglobin (Hgb) <12.0 g/dl in non-pregnant women and <13.0 g/dl in men based on the World Health Organization (WHO) criteria (26).

Treatment

Five patients initially underwent limb-sparing surgery, amputation was performed for one patient, and disarticulation was performed for one patient. Surgical excision margins were estimated based on the AJCC residual tumor classification (R classification) (27). These surgical margins were classified as follows: R0 margin, free of malignancy; R1 margin, microscopic tumor cells present at the inked border of the specimen; and R2 margin, grossly positive margins. Surgical margins were estimated as R0 in all patients. Soft tissue coverage was required in four patients: two free flaps (latissimus dorsi flap), one medial gastrocnemius muscle flap and skin graft, and one skin graft. Since all patients achieved R0 resection, radiation therapy was not performed for any of the patients. No patients received pre- or postoperative chemotherapy.

Statistical analysis

The Mann-Whitney U test was used to analyze continuous parameters, while Fisher's exact test was used for categorical parameters. We used the BellCurve for Excel (Social Survey Research Information Co., Ltd.) for all the analyses. The overall survival (OS) was calculated from the date of diagnosis to the date of death or the last follow-up visit. Survival rates were estimated using the Kaplan-Meier method. A P-value of <0.05 was considered statistically significant.

Results

Microbiological analyses

Microbiological sampling from the wound was performed prior to surgery for five patients and 11 different bacterial strains were identified in them (Table IV). The average number of bacterial strains isolated per wound was 2.6 (1 aerobic, 1.6 anaerobic species). The aerobic bacteria identified included Pseudomonas aeruginosa, Alcaligenes faecalis, Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Bacillus cereus (all of these were isolated in one patient). The facultative anaerobic bacteria were methicillin-sensitive Staphylococcus aureus (MSSA; three patients), Enterococcus faecalis, Enterobacter cloacae, Streptococcus dysgalactiae, and Proteus vulgaris (all isolated from all wounds). The strict anaerobic bacterial species was Peptostreptococcus asaccharolyticus (one patient). Preoperative blood culture performed in one patient was negative. Antibiotics were selected and administered for four patients (cases 1–4) based on the preoperative antibiotic sensitivity test (Table IV).

Table IV.

Microbiological analyses and antibiotics.

Table IV.

Microbiological analyses and antibiotics.

A, Initial presentation

CaseSamplingBacterial strainAntibiotics
1WoundPseudomonas aeruginosa Enterococcus faecalis Alcaligenes faecalisLevofloxacin hydrate
2Wound Methicillin-sensitive Staphylococcus aureus Streptococcus dysgalactiaeClindamycin + Cefazolin sodium → Cefazoplan
BloodNegative
3Wound Methicillin-sensitive Staphylococcus aureus Bacillus cereusCefazolin sodium
4Wound Methicillin-sensitive Staphylococcus aureus Proteus vulgarisCefazolin sodium
6WoundEnterobacter cloacae Acinetobacter baumannii complex Stenotrophomonas maltophilia Peptostreptococcus asaccharolyticusCefazolin sodium

B, Surgical site infection

Case SamplingBacterial strain Antibiotics

1WoundPseudomonas aeruginosa Enterococcus faecalis-
2Wound Methicillin-sensitive Staphylococcus aureusMeropenem
3Initial surgery
  Wound, blood, urinePseudomonas aeruginosaMeropenem
Recurrence
  WoundPseudomonas aeruginosaMeropenem
  BloodNegative
Surgical Site Infection

Surgical site infection (SSI) occurred in three patients (43%), including two patients with superficial incisional SSI and one with deep incisional SSI. It was observed in 3/5 patients with exudate, but none in those without exudate. All three patients had received preoperative sensitivity-guided perioperative antibacterial prophylaxis. The bacterial isolates from MWs and surgical sites were identical in two of three patients (MSSA and Pseudomonas aeruginosa) and in one other patient (Pseudomonas aeruginosa). One patient (case 1) had levofloxacin-sensitive Pseudomonas aeruginosa and Alcaligenes faecalis cultured from the wound at the initial presentation, and was given levofloxacin hydrate preoperatively. Five days after resection and skin graft, Pseudomonas aeruginosa was cultured from the exudate of the grafted skin. Saline washing was performed and the wound healed without delay. In another patient (case 2), MSSA and Streptococcus dysgalactiae were isolated from the wound at the initial presentation. Pus was observed in the separated wound after one month of the hip disarticulation, from which MSSA was cultured. Irrigation, debridement, and intravenous meropenem resolved the deep incisional infection. In another patient (case 3), MSSA and Bacillus cereus were cultured from the wound at the initial presentation. Resection following reconstruction with free flap and skin graft was performed and cefazolin sodium, to which MSSA was sensitive, was given one day prior to surgery up to four days postoperatively. Fever continued after surgery, and Pseudomonas aeruginosa was isolated from the exudate of the grafted skin, in blood, and urine. The wound improved after saline washing and meropenem administration. The patient developed MWs from the recurrence 2.5 years later, for which hip disarticulation was performed. Pus was observed from the separated wound one month after surgery, and Pseudomonas aeruginosa was cultured from the wound. Irrigation and debridement were performed and meropenem was administered, which cured the deep incisional infection.

Laboratory investigation

The values of the laboratory tests for each patient are shown in Table SII. Four patients presented with elevated WBC count (average; 10169/µl, range: 5820-14820/µl), which decreased to the normal value within three weeks after surgery for all patients (Fig. 1A). Five patients presented with elevated CRP (average; 8.4 mg/dl, range: 0.11-27.7 mg/dl), which decreased to the normal value in three patients and was less than 1 mg/dl in the other two patients after surgery (Fig. 1B). Four patients presented with low Hgb, which was diagnosed as anemia (average; 11.4 g/dl, range: 8.2-14.4 g/dl) (Fig. 1C). Four patients received RBC transfusions. The value of Hgb improved in three patients, though new asymptomatic anemia was seen in two patients after surgery. Two patients presented with elevated levels of BUN (average; 18.4 mg/dl, range: 9.7-43.5 mg/dl), which improved to within normal limits within one week after surgery in both the patients (Fig. 1D). Cr was within the normal range (average; 0.77 mg/dl, range: 0.53-0.96 mg/dl) in all patients during the first presentation and after surgery (Fig. 1E). Six patients presented with low Alb levels (average; 3.2 g/dl, range: 1.6-3.9 g/dl), which improved in three patients after surgery (Fig. 1F). ALT was within the normal range (average; 19 g/dl, range: 6–38 g/dl) during the first presentation, and one patient had transient elevation after surgery (Fig. 1G). All but one patient presented with elevated AST (average; 23 g/dl, range: 11–56 g/dl), which improved within five weeks after surgery (Fig. 1H). Two patients had transient elevation after surgery. All but one patient presented with elevated T-bil (average; 0.98 mg/dl, range: 0.47-2.3 mg/dl), which improved to the normal value one week after surgery (Fig. 1I), and significantly decreased two weeks after surgery (P=0.04).

Figure 1.

Laboratory results. The levels of WBC, CRP, Hgb, BUN, Cr, Alb, ALT, AST and T-bil were investigated at the initial presentation and after surgery (2–6 weeks). (A) A total of four patients presented with elevated WBC count (average 10169/µl), which decreased to the normal range within three weeks after surgery in all patients. (B) A total of five patients presented with elevated CRP (average 8.4 mg/dl), which decreased over time. (C) Four patients presented with low Hgb and were diagnosed as having anemia (average 11.4 g/dl). The level of Hgb improved in three patients. (D) Two patients presented with elevated BUN (average 18.4 mg/dl), which normalized within one week after surgery. (E) Cr was within the normal range (average 0.77 mg/dl) in all patients during the first presentation and after surgery. (F) Six patients presented with low Alb (average 3.2 g/dl), which improved in three patients after surgery. (G) ALT was within the normal value (average 19 g/dl), and one patient experienced transient elevation after surgery. (H) All patients, except for one, presented with elevated AST (average 23 g/dl), which improved within five weeks after surgery. (I) All patients, except for one, presented with elevated T-bil (average 0.98 mg/dl), which improved to within normal limits one week after surgery, and significantly decreased two weeks after surgery. *P=0.04. Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; CRP, C-reactive protein; Hgb, hemoglobin; T-bil, total bilirubin; WBC, white blood cell.

Prognosis

Among the seven patients, one experienced local recurrence after 4 months, and underwent re-excision of the recurrent lesion. Three patients had distant metastases at presentation: lymph node metastasis in two patients, lung metastasis in one patient, and bone metastasis in one patient. Two patients developed distant metastases during the follow-up period, including lymph node metastasis in one patient, lung metastasis in one patient, and soft tissue in one patient. Four patients died before the last follow-up. The 5-year OS rate was 71% (Fig. 2).

Case 1

The patient was a 42-year-old woman with MW from a myxoid liposarcoma in the thigh. She was quickly transported to the hospital because of pain and fatigue. She had a large tumor in her left thigh with bleeding, odor, and exudate on the overlying skin (Fig. 3A and B), and was referred to our institution. MRI revealed a mass with high intensity on T2-weighted images (Fig. 3C and D). CT revealed multiple lesions in both lungs. Although the patient was conscious (Glasgow Coma Score of 15), she was pale and had abnormal vital signs: fever (39°C), low systolic blood pressure (89 mmHg), tachycardia (123/min), and hyperpnea (38/min). She also had low oxygen saturation (96%). Laboratory examination showed elevation of WBC (14820/µl), CRP (27.7 mg/dl), BUN (43.5 mg/dl), AST (56 U/l), and T-bil (2.3 mg/dl), low value of Hgb (8.2g/dl) and Alb (1.6 g/dl), and normal levels of ALT and Cr. Infection was suspected in the presence a qSOFA score of 2 at presentation. The patient received red blood cell (RBC) transfusions and infusion. A diagnosis of sepsis was confirmed by a SOFA score of 2. Culture from the wound revealed MSSA and Streptococcus dysgalactiae, for which clindamycin and cefazolin sodium were given. Improvement was seen in both clinical status and abnormal laboratory values. Needle biopsy revealed myxoid liposarcoma. Hip disarticulation was performed four days later, and all abnormal values of laboratory examinations improved after surgery. Antibiotics were changed to cefazolin after surgery, which was given for seven days.

Case 6

The patient was a 78-year-old man who was referred to our institution for further examination of MW from a myxofibrosarcoma in the upper arm. He had a large tumor in his right upper arm with odor and exudate on the wounded overlying skin (Fig. 4A). MRI revealed a mass with high intensity on T2-weighted images (Fig. 4B and C). Laboratory examination showed elevation of, CRP (15.1 mg/dl), low value of Hgb (9.5 g/dl) and Alb (2.5 g/dl). Culture from the wound revealed polymicrobial etiology: Enterobacter cloacae, Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Peptostreptococcus asaccharolyticus. Wide resection and free flap (latissimus dorsi flap) were performed. Cefazolin sodium was given for 7 days postoperatively. Improvement was seen in abnormal laboratory values after surgery. Lymph node metastasis was documented four years later, which was excised, and the patient had remained disease-free at the last follow up.

Discussion

Fromantin et al identified polymicrobial flora composed of 54 different bacterial types in the microbiological analyses of MWs of breast cancer. The study reported that the average number of bacteria per patient was 3.6 aerobic species and 1.7 anaerobic species, with a predominance of Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium striatum, and Proteus mirabilis (4). Lutchminarian et al reported that the most common pathogen in the wound was Staphylococcus aureus (33%), followed by β-hemolytic Streptococcus (17%) and Pseudomonas aeruginosa (17%) in patients with MWs of STS (13). Similar to these reports, we found that MSSA was the most commonly isolated species, followed by Pseudomonas aeruginosa and Enterococcus faecalis. Moreover, we first showed that MWs of STS were polymicrobial in etiology, with an average number of bacteria per patient was 2.6, including 1 aerobic species and 1.6 anaerobic species.

We found that SSI occurred in three of the seven patients (43%). This high rate of SSI is in line with a previous report in which SSI was found to be in as many as 26–42% of patients with MWs (15,18). There are numerous reports investigating the risk factors associated with SSI (2830). According to the international consensus on orthopedic infection by the Musculoskeletal Infection Society, the risk of developing SSI is influenced by several factors, such as malignancy, malnutrition, preoperative anemia, age (>75 years), and a history of diabetes mellitus (DM) (28). In a systematic review, risk factors associated with SSI among surgical patients include high body mass index, National Nosocomial Infections Surveillance risk index (contamination class, American Society of Anesthesiologists class, and operative time), and a history of DM (30). In this study, patients with MWs had multiple accompanying factors, including malignancy (100%), contaminated or dirty wound (100%), malnutrition with low albumin (86%), and anemia (57%), which would lead to a high SSI rate. Hoshi et al reported that Candida species were detected most commonly, followed by Pseudomonas aeruginosa and Enterococcus species from the infected surgical site (18). In this study, we found Pseudomonas aeruginosa in two patients and MSSA in one patient from the infected surgical site. We compared the bacterium both in the preoperative wound and the surgical site and found that two of the three patients with SSI had identical isolates on both sites. These three patients had received perioperative prophylaxis. However, it was unclear whether the perioperative antibiotic prophylaxis could be attributed in preventing SSI in patients with MWs. The limited efficacy of systemic antibiotic injections may be due to the necrotic tissue, avascular environment of MWs, and the biofilm (31). Once bacteria adhere to the surface of the tissue or prosthetic materials, they form microcolonies (3133). Next, they produce an extracellular polymeric matrix and encase themselves in the matrix (33). Bacteria that form biofilms and colonize or infect medical devices or wounds are particularly difficult to treat as biofilms are highly resistant to antibiotics (3234). Several pharmaceutical interventions for reducing the microbial concentration in the wound have been investigated in patients with MWs to avoid wound contamination of potentially colonized bacterium (3234). Recently, the use of metronidazole, which is deemed effective in eliminating anaerobes, has been shown to be effective in improving odor in 83–95% of patients (35,36). In a multicenter, open-label, phase III study conducted among patients with unresectable breast cancer, head and neck cancer, skin cancer, and STS, Watanabe et al reported that 95% of the patients experienced relief with respect to severity of odor by using topical metronidazole 0.75% gel (36). Mohs' paste has also been shown to be effective for controlling MWs from various malignant tumors, including STS (68). It is mainly composed of zinc chloride and was originally developed for curative treatment via repeated fixation and excision until there is complete removal of the tumor (6). Hoshi et al reported success in the combined treatment using Mohs' paste and neoadjuvant chemotherapy for undifferentiated pleomorphic sarcoma arising in the right chest wall (9). Systemic chemotherapy and Mohs' paste led to significant shrinkage of the tumor and received wide resection and reconstruction with a rectus abdominis musculocutaneous flap. In this study, we did not utilize these agents prior to surgery. As patients with MWs frequently require soft tissue coverage for large defects after resection, it is necessary to adjust the schedule of plastic surgery, as it is not possible to remove it immediately. The pharmacologic agents may be considered for control of both tumor and the infection when surgery cannot be performed immediately (33). The efficacy of these agents for reducing SSI should be further investigated using randomized controlled trials in the future.

We found that patients with MWs of STS had various symptoms. They had bleeding (71%), exudated (71%), or developed an odor (43%) at the initial presentation. However, these symptoms disappeared after surgery. All except for one patient experienced pain at the site of the MWs on initial presentation, with an average NRS of 4.4. The NRS decreased after surgery, with an average of 1.4 (P=0.14) and 0.6 (P=0.04) one and two weeks after surgery, respectively., All but one patient had pain at the surgical site at the last follow-up. Two patients presented with fever, which improved one week after surgery. Regarding laboratory results, the patients had elevated CRP level (71%), anemia (57%), malnutrition with low albumin (86%), and renal or liver disturbances (14–29%). These abnormal laboratory values could have been due to the complex effect of both the tumor and infection. We found that these abnormal laboratory values were reversible, as most of them improved after surgery. Then, we think the tumor with MWs should be excised completely if possible.

In this study, one patient was diagnosed with sepsis and required emergency treatment. Although she had poor general condition at the first presentation to the hospital, RBC transfusion and infusion could improve the hemodynamics. In case of MWs at the first presentation, the microbiological condition is sometimes underrecognized or underestimated because physicians tend to focus on investigating the oncological condition of the patient (9). However, physicians should consider that MWs can potentially turn into a life-threatening condition when complicated by sepsis. Clinical parameters, such as vital signs, laboratory results, bacterial culture from the wound should be examined promptly to manage the patients adequately.

We found some studies which highlight the oncological implications of MWs of STS (1518). In these previous reports, patients with MWs of STS presented with high proportion of metastases (20–33%) and had a poor prognosis with a 5-year OS of 15–26% (1518). Potter et al compared the oncological outcomes between the MWs group and the non-MWs group and found that patients with MWs from STS presented with a higher rate of metastases (33% in the MWs group and 9% in the non-MWs group; P=0.003) and had a poor prognosis (5-year OS of 20% in the MWs group and 63% in the non-MWs group; P<0.0001) (16). Similarly, Parry et al reported that prognosis of patients with MWs was poor compared to that of without MWs (5-year OS of 15% in the MWs group and 66% in the non-MWs group; P<0.0001) (17). They also reported that MW was associated with poor prognosis as an independent risk factor. In line with previous reports (1518), three out of seven patients in our study had distant metastases during presentation. All patients had high-grade sarcoma and a relatively large tumor size (>5 cm), and three patients died because of the disease before the last follow-up, with a 5-year OS rate of 71%. However, limb salvage may be difficult for bulky tumors, which often increases the risk of amputation (20–33%). In previous reports, 48–60% of patients required plastic surgery, including skin graft or flap in limb-sparing surgery (1518). In the current study, five patients initially underwent limb-sparing surgery, and four patients required skin graft or flap.

This study has some limitations. First, it has a small sample size of only seven patients. MW occur in 3–4% STS. Therefore, it was difficult to include enough cases for this study. Second, we did not investigate the biofilms in the MWs. Since, this is a retrospective study, we had not investigated the biofilms in this series of the patients. Third, due to the retrospective study we had not investigated the preoperative microbiological samples from the necrotic zone of the wound in all patients. However, we showed that the MWs of STS had a polymicrobial etiology with an average number of bacteria per patient was 2.6, and predominance of Staphylococcus aureus and Pseudomonas aeruginosa, consistence with previous reports. Fourth, we could not determine the effectiveness of selected antibiotics in preventing SSI in patients with MWs, since not all patients received perioperative prophylaxis. Their effectiveness in preventing SSI needs to be investigated in the future. Despite these limitations, this is the first report investigating perioperative clinical symptoms, laboratory examination, and the bacterial landscape in patients with MWs of STS.

In conclusion, MW is composed of high-grade sarcoma and polymicrobial colonization. Physicians should consider that MWs can possibly lead to life-threatening conditions when complicated by sepsis; therefore, clinical and laboratory examinations should be performed promptly to manage patients adequately. Although patients presented with various symptoms and showed abnormal values in laboratory examination, they might improve after surgical resection. The effectiveness of the selected antibiotics based on the results of the preoperative culture in preventing SSI needs to be investigated in the future in patients with MWs.

Supplementary Material

Supporting Data

Acknowledgements

Not applicable.

Funding

Funding: No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

EN, TK, and TO designed the study. EN, TF and TK treated the patients. EN, HK and TI collected and analyzed data. EN and TK confirmed the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval statement and consent to participate

This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Okayama University Hospital approved this study (approval no. K2104-020). Patients provided written informed consent for their participation in this study.

Patient consent for publication

Written informed consent was obtained from each participant included in this study.

Competing interests

The authors declare that they have no competing interests.

References

1 

Alexander S: Malignant fungating wounds: Epidemiology, aetiology, presentation and assessment. J Wound Care. 18:273–274. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Alvarez O, Kalinski C, Nusbaum J, Hernandez L, Pappous E, Kyriannis C, Parker R, Chrzanowski G and Comfort CP: Incorporating wound healing strategies to improve palliation (symptom management) in patients with chronic wounds. J Palliat Med. 10:1161–1189. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Vardhan M, Flaminio Z, Sapru S, Tilley CP, Fu MR, Comfort C, Li X and Saxena D: The microbiome, malignant fungating wounds, and palliative care. Front Cell Infect Microbiol. 9:3732019. View Article : Google Scholar : PubMed/NCBI

4 

Fromantin I, Seyer D, Watson S, Rollot F, Elard J, Escande MC, De Rycke Y, Kriegel I and Larreta Garde V: Bacterial floras and biofilms of malignant wounds associated with breast cancers. J Clin Microbiol. 51:3368–3373. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Finlayson K, Teleni L and McCarthy AL: Topical opioids and antimicrobials for the management of pain, infection, and infection-related odors in malignant wounds: A systematic review. Oncol Nurs Forum. 44:626–632. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Mohs FE, Sevringhaus EL and Schmidt ER: Conservative amputation of gangrenous parts by chemosurgery. Ann Surg. 114:274–282. 1941. View Article : Google Scholar : PubMed/NCBI

7 

Mohs FE: Chemosurgical treatment of cancer of the extremities and trunk; a microscopically controlled method of excision. Arch Surg (1920). 57:818–832. 1948. View Article : Google Scholar : PubMed/NCBI

8 

Nemoto K, Okamoto M, Kito M, Aoki K, Suzuki S, Takazawa A, Yoshimura Y and Kato H: Combined treatment using Mohs' paste and neoadjuvant chemotherapy for giant gluteal soft tissue sarcoma with malignant fungating wound: A case report. J Surg Case Rep. 2019:rjz1372019. View Article : Google Scholar : PubMed/NCBI

9 

Hoshi M, Iwai T, Oebisu N and Nakamura H: Successful pre-operative local control of skin exposure by sarcoma using combination of systemic chemotherapy and Mohs' chemosurgery. World J Surg Oncol. 18:362020. View Article : Google Scholar : PubMed/NCBI

10 

Bower M, Stein R, Evans TR, Hedley A, Pert P and Coombes RC: A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. Eur J Cance. 28A:888–889. 1992. View Article : Google Scholar : PubMed/NCBI

11 

Kalinski C, Schnepf M, Laboy D, Hernandez L, Nusbaum J, McGrinder B, Comfort C and Alvarez OM: Effectiveness of a topical formulation containing metronidazole for wound odor and exudate control. Wounds. 17:84–90. 2005.

12 

Ashford R, Plant G, Maher J and Teare L: Double-blind trial of metronidazole in malodorous ulcerating tumours. Lancet. 1:1232–1233. 1984. View Article : Google Scholar : PubMed/NCBI

13 

Lutchminarian K and Clarke DL: The microbiology of ulcerative skin cancers: Does the presence of pathogenic bacteria increase the risk of postoperative complications? S Afr J Surg. 59:25a–25e. 2021. View Article : Google Scholar : PubMed/NCBI

14 

Elfallal AH, Laimon YN and Emile SH: Giant angiolipoma of the back complicated with ulceration and sepsis: Unusual presentation of a rare benign tumour. Ann R Coll Surg Engl. 101:e91–e93. 2019. View Article : Google Scholar : PubMed/NCBI

15 

Okajima K, Kobayashi H, Okuma T, Arai S, Zhang L, Hirai T, Ishibashi Y, Ikegami M, Shinoda Y, Akiyama T, et al: Prognosis and surgical outcome of soft tissue sarcoma with malignant fungating wounds. Jpn J Clin Oncol. 51:78–84. 2021. View Article : Google Scholar : PubMed/NCBI

16 

Potter BK, Adams SC, Qadir R, Pitcher JD and Temple HT: Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration. J Bone Joint Surg Am. 91:567–574. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Parry M, Evans S, Sugath S, Wafa H, Jeys L and Grimer R: Fungation in soft tissue sarcomas is associated with poor survival. Int Orthop. 41:2613–2618. 2017. View Article : Google Scholar : PubMed/NCBI

18 

Hoshi M, Oebisu N, Iwai T, Ieguchi M and Nakamura H: Clinical course of soft tissue sarcomas presenting as malignant wounds. J Orthop Sci. 24:1088–1093. 2019. View Article : Google Scholar : PubMed/NCBI

19 

Fletcher CD, Bridge JA, Hogendoorn P and Mertens F: WHO Classification of Tumours of soft tissue and bone. 4th edition. IARC Press; Lion: 2013

20 

Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, et al: Comparative study of the National cancer institute and french federation of cancer centers sarcoma group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 15:350–362. 1997. View Article : Google Scholar : PubMed/NCBI

21 

Mangram AJ, Horan TC, Pearson ML, Silver LC and Jarvis WR: Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 20:250–278. 1999. View Article : Google Scholar : PubMed/NCBI

22 

Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, Kakihana Y, Kawasaki T, Kushimoto S, Kuroda Y, et al: The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020). J Intensive Care. 9:532021. View Article : Google Scholar : PubMed/NCBI

23 

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 45:486–552. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, et al: Assessment of Clinical criteria for sepsis: For the Third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 315:762–774. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Pandharipande PP, Sanders N, Jacques P, Ely EW and Shintani A: Calculating SOFA scores when arterial blood gasses are not available: Validating SpO2/FIO2 ratios for imputing PaO2/FIO2 ratios in the SOFA scores. Crit Care Med. 34:A12006. View Article : Google Scholar

26 

Pasricha SR, Colman K, Centeno-Tablante E, Garcia-Casal MN and Peña-Rosas JP: Revisiting WHO haemoglobin thresholds to define anaemia in clinical medicine and public health. Lancet Haematol. 5:e60–e62. 2018. View Article : Google Scholar : PubMed/NCBI

27 

Wittekind C, Compton C, Quirke P, Nagtegaal I, Merkel S, Hermanek P and Sobin LH: A uniform residual tumor (R) classification: Integration of the R classification and the circumferential margin status. Cancer. 115:3483–3488. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Zainul-Abidin S, Amanatullah DF, Anderson MB, Austin M, Barretto JM, Battenberg A, Bedard NA, Bell K, Blevins K, Callaghan JJ, et al: General assembly, prevention, host related general: Proceedings of International consensus on orthopedic infections. J Arthroplasty. 34:S13–S35. 2019. View Article : Google Scholar : PubMed/NCBI

29 

Chauveaux D: Preventing surgical-site infections: Measures other than antibiotics. Orthop Traumatol Surg Res. 101 (Suppl 1):S77–S83. 2015. View Article : Google Scholar : PubMed/NCBI

30 

Korol E, Johnston K, Waser N, Sifakis F, Jafri HS, Lo M and Kyaw MH: A systematic review of risk factors associated with surgical site infections among surgical patients. PLoS One. 8:e837432013. View Article : Google Scholar : PubMed/NCBI

31 

Ramasubbu DA, Smith V, Hayden F and Cronin P: Systemic antibiotics for treating malignant wounds. Cochrane Database Syst Rev. Aug 24–2017.(Epu. View Article : Google Scholar : PubMed/NCBI

32 

Schierle CF, De la Garza M, Mustoe TA and Galiano RD: Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model. Wound Repair Regen. 17:354–359. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Salisbury AM, Woo K, Sarkar S, Schultz G, Malone M, Mayer DO and Percival SL: Tolerance of biofilms to antimicrobials and significance to antibiotic resistance in wounds. Surg Technol Int. 33:59–66. 2018.PubMed/NCBI

34 

Hughes G and Webber MA: Novel approaches to the treatment of bacterial biofilm infections. Br J Pharmacol. 174:2237–2246. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Villela-Castro DL, Santos VLCG and Woo K: Polyhexanide versus metronidazole for odor management in malignant (fungating) wounds: A double-blinded, randomized, clinical trial. J Wound Ostomy Continence Nurs. 45:413–418. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Watanabe K, Shimo A, Tsugawa K, Tokuda Y, Yamauchi H, Miyai E, Takemura K, Ikoma A and Nakamura S: Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75% gel (GK567): A multicenter, open-label, phase III study (RDT.07.SRE.27013). Support Care Cancer. 24:2583–2590. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nakata E, Fujiwara T, Katayama H, Itano T, Kunisada T and Ozaki T: Effect of bacterium in the malignant wounds of soft tissue sarcoma. Oncol Lett 24: 345, 2022
APA
Nakata, E., Fujiwara, T., Katayama, H., Itano, T., Kunisada, T., & Ozaki, T. (2022). Effect of bacterium in the malignant wounds of soft tissue sarcoma. Oncology Letters, 24, 345. https://doi.org/10.3892/ol.2022.13465
MLA
Nakata, E., Fujiwara, T., Katayama, H., Itano, T., Kunisada, T., Ozaki, T."Effect of bacterium in the malignant wounds of soft tissue sarcoma". Oncology Letters 24.4 (2022): 345.
Chicago
Nakata, E., Fujiwara, T., Katayama, H., Itano, T., Kunisada, T., Ozaki, T."Effect of bacterium in the malignant wounds of soft tissue sarcoma". Oncology Letters 24, no. 4 (2022): 345. https://doi.org/10.3892/ol.2022.13465